Summary

Milnacipran may be an effective treatment for the fatigue that is associated with fibromyalgia (FM). FM is a chronic disorder with symptoms, including musculoskeletal pain and allodynia, as well as debilitating fatigue. Milnacipran is a dual reuptake inhibitor of serotonin and norepinephrine that is used for the treatment of FM. This article discusses an evaluation the effect of milnacipran on fatigue in patients with FM (as determined by American College of Rheumatology criteria) in a pooled analysis of three Phase III trials.